Typhoid Fever Clinical Trial
Official title:
A Cluster-randomised Controlled Phase IV Trial Assessing the Impact of a Vi-Polysaccharide Conjugate Vaccine in Preventing Typhoid Infection in Asante Akim, Ghana (TyVEGHA)
A cluster-randomised controlled Phase IV trial (cRCT) assessing the impact of a Vi-Polysaccharide conjugate vaccine in preventing typhoid infection in Asante Akim, Ghana (TyVEGHA) with a primary endpoint of determining the total protection conferred by single-dose vaccination with Vi-TT against blood culture-confirmed symptomatic S. Typhi infection in the intervention vaccine clusters, compared with the control vaccine clusters.
Typhoid fever remains a significant health problem in sub-Saharan Africa, with incidence rates >100 cases per 100,000 person-years of observation. Despite the prequalification of safe and effective typhoid conjugate vaccines (TCV), the uptake of these vaccines in African countries has remained low. Real-life effectiveness data, which inform public health programs on the impact of TCVs in reducing typhoid-related mortality and morbidity, are critical to enhancing the introduction of TCVs in high-burden settings. Here we describe a cluster-randomized trial to investigate population-level protection of TCV against blood culture-confirmed typhoid fever. A total of 80 geographically distinct clusters have been delineated within the Agogo district of the Asante Akim region in Ghana. Clusters will be randomized to the intervention arm receiving TCV or a control arm receiving the meningococcal A conjugate vaccine. The primary study endpoint is the overall protection of TCV against blood culture-confirmed typhoid fever. Total, direct, and indirect protection will be measured as secondary outcomes. Blood culture-based enhanced surveillance will enable the estimation of incidence rates in the intervention and control clusters. Evaluation of the real-world impact of TCVs will improve uptake of prequalified/licensed safe and effective typhoid vaccines in public health programs of high burden settings. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04830371 -
Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04543877 -
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
|
Early Phase 1 | |
| Completed |
NCT02324751 -
Vaccines Against Salmonella Typhi
|
Phase 2 | |
| Completed |
NCT01421693 -
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
|
Phase 4 | |
| Completed |
NCT05579821 -
Evaluation Study of DPP® Typhoid Assay
|
||
| Completed |
NCT02947295 -
Global Genomic and Proteomic Profiling of African Children With Typhoid Fever
|
||
| Completed |
NCT01405521 -
Understanding Typhoid Disease After Vaccination
|
Phase 2 | |
| Completed |
NCT00386789 -
Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age
|
N/A | |
| Completed |
NCT04801602 -
Commercial Typhoid Tests Validation Trial
|
||
| Recruiting |
NCT06104345 -
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
|
Phase 4 | |
| Completed |
NCT01438996 -
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
|
Phase 2 | |
| Completed |
NCT01437267 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
|
Phase 2 | |
| Completed |
NCT01193907 -
Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
|
Phase 2 | |
| Recruiting |
NCT04349826 -
The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
|
Phase 4 | |
| Completed |
NCT01608815 -
Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
|
Phase 3 | |
| Completed |
NCT01123941 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
|
Phase 1 | |
| Recruiting |
NCT05500482 -
Vellore Typhoid Vaccine Impact Trial
|
Phase 4 | |
| Completed |
NCT03926455 -
Safety and Immunogenicity of Typhax, a Typhoid Vaccine
|
Phase 1 | |
| Completed |
NCT01229176 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
|
Phase 2 | |
| Completed |
NCT03956524 -
Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults
|
Phase 1 |